Current Oncology (Oct 2023)

Safety and Efficacy of Hepatic Artery Embolization in Heavily Treated Patients with Intrahepatic Cholangiocarcinoma: Analysis of Clinicopathological and Radiographic Parameters Associated with Better Overall Survival

  • Sara Velayati,
  • Ahmed Elsakka,
  • Ken Zhao,
  • Joseph P. Erinjeri,
  • Brett Marinelli,
  • Mohamed Soliman,
  • Olivier Chevallier,
  • Etay Ziv,
  • Lynn A. Brody,
  • Constantinos T. Sofocleous,
  • Stephen B. Solomon,
  • James J. Harding,
  • Ghassan K. Abou-Alfa,
  • Michael I. D’Angelica,
  • Alice C. Wei,
  • Peter T. Kingham,
  • William R. Jarnagin,
  • Hooman Yarmohammadi

DOI
https://doi.org/10.3390/curroncol30100663
Journal volume & issue
Vol. 30, no. 10
pp. 9181 – 9191

Abstract

Read online

The safety and efficacy of hepatic artery embolization (HAE) in treating intrahepatic cholangiocarcinoma (IHC) was evaluated. Initial treatment response, local tumor progression-free survival (L-PFS), and overall survival (OS) were evaluated in 34 IHC patients treated with HAE. A univariate survival analysis and a multivariate Cox proportional hazard analysis to identify independent factors were carried out. Objective response (OR) at 1-month was 79.4%. Median OS and L-PFS from the time of HAE was 13 (CI = 95%, 7.4–18.5) and 4 months (CI = 95%, 2.09–5.9), respectively. Tumor burden p < 0.05). Multivariate logistic regression analysis demonstrated that tumor burden < 25% and hypervascular tumors were independent risk factors. Mean post-HAE hospital stay was 4 days. Grade 3 complication rate was 8.5%. In heavily treated patients with IHC, after exhausting all chemotherapy and other locoregional options, HAE as a rescue treatment option appeared to be safe with a mean OS of 13 months. Tumor burden < 25%, increased target tumor vascularity on pre-procedure imaging, and OR on 1 month follow-up images were associated with better OS. Further studies with a control group are required to confirm the effectiveness of HAE in IHC.

Keywords